Pre‐ and post‐treatment FDG PET‐CT as a predictor of patient outcomes in anal squamous cell carcinoma: A systematic review and meta‐analysis
Journal of Medical Imaging and Radiation Oncology · 2023-09 · 67 (6) · 634-646
DOI: 10.1111/1754-9485.13566 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, online erschienen am 13.08.2023. Verfasst von Benjamin M Mac Curtain und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, St John of God Subiaco Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Anus Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Anal squamous cell carcinoma (ASCC) has a generally acceptable outlook in terms of survival. 18‐fluorodeoxyglucose‐positron emission tomography/computer tomography (FDG PET‐CT) is not recommended for routine monitoring post‐ASCC treatment. We examine herein if FDG PET‐CT has a use in the prognostic evaluation of patients with ASCC, what FDG PET‐CT metrics are of value and if a pre‐ or post‐chemo/radiotherapy scan is more prognostic of outcomes. PubMed, EMBASE and Cochrane Central Registry of Controlled Trials were comprehensively searched until 3 May, 2023. A modified Newcastle Ottawa scale was used to assess for study bias. We present our systematic review alongside pooled hazard ratios (HR) for maximum standardised uptake values (SUV) as a predictor of overall survival (OS) and progression‐free survival (PFS). Seven studies including 523 patients were included in our systematic review. Current evidence suggests that SUV maximum and median, metabolic tumour volume, total lesion glycolysis and complete and partial metabolic response may be prognostic when considering overall or progression‐free survival (OS)/(PFS) along with local recurrence (LR). Pooled HR from two included studies indicate SUV max is prognostic of OS, HR 1.179, CI (1.039–1.338), P = 0.011 and PFS 1.176, CI (1.076–1.285), P < 0.01. FDG PET‐CT may have a role to play in the prognostic evaluation of ASCC patients. Current evidence suggests post‐treatment scanning may hold superior prognostic value at this time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, St John of God Subiaco Hospital, Perth, Western Australia, Australia.
- Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
- Department of General Surgery, Royal Perth Hospital, Perth, Western Australia, Australia.
- School of Medicine, The University of New South Wales, Sydney, New South Wales, Australia.
ORCID-Profile: Benjamin M Mac Curtain, Hugo C Temperly
Zitieren
APA
Mac Curtain, B. M., Qian, W., Bell, J., O'Mahony, A., Temperly, H. C., & Ng, Z. Q. (2023). Pre‐ and post‐treatment FDG PET‐CT as a predictor of patient outcomes in anal squamous cell carcinoma: A systematic review and meta‐analysis. Journal of Medical Imaging and Radiation Oncology, 67(6), 634-646. https://doi.org/10.1111/1754-9485.13566
Vancouver
Mac Curtain BM, Qian W, Bell J, O'Mahony A, Temperly HC, Ng ZQ. Pre‐ and post‐treatment FDG PET‐CT as a predictor of patient outcomes in anal squamous cell carcinoma: A systematic review and meta‐analysis. Journal of Medical Imaging and Radiation Oncology. 2023;67(6):634-646. doi:10.1111/1754-9485.13566
BibTeX
@article{MacCurtain2023,
author = {Mac Curtain, Benjamin M and Qian, Wanyang and Bell, Jack and O'Mahony, Aaron and Temperly, Hugo C and Ng, Zi Qin},
title = {Pre‐ and post‐treatment FDG PET‐CT as a predictor of patient outcomes in anal squamous cell carcinoma: A systematic review and meta‐analysis},
journal = {Journal of Medical Imaging and Radiation Oncology},
year = {2023},
volume = {67},
number = {6},
pages = {634--646},
doi = {10.1111/1754-9485.13566}
}
EUVIMED